Adjuvant chemotherapy for patients with rectal cancer – will the controversy be resolved?

References

• NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444–50.
   PubMed Web of Science ®Google Scholar
• NCI. Clinical announcement. Adjuvant therapy of rectal cancer, March 14. Bethesda, Maryland, US: National Cancer Institute; 1991.
   Google Scholar
• Glimelius B. Adjuvant chemotherapy in rectal cancer – an issue or a non-issue? Ann Oncol 2010;21:1739–41.
   PubMed Web of Science ®Google Scholar
• Breugom AJ, van de Velde CJ. Adjuvant chemotherapy for patients with rectal cancer? Lancet Oncol 2014;15:1185–6.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Tiret E, Cervantes A, Arnold D. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi81–8.
   Google Scholar
• NICE. Colorectal cancer: The diagnosis and management of colorectal cancer. [cited 2015 Feb 25]. Available from: https://www.nice.org.uk/guidance/cg131/resources/guidance-colorectal-cancer-pdf 2015.
   Google Scholar
• NCCN clinical practice guidelines in oncology rc. [cited 2015 Feb 25]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf 2015
   Google Scholar
• Glimelius B. 50 years with Acta Oncologica. Acta Oncol 2013;52:1–2.
   PubMed Web of Science ®Google Scholar
• Glimelius B. The 50-year anniversary of Acta Oncologica. Acta Oncol 2014;53:1–2.
   PubMed Web of Science ®Google Scholar
• Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 2014;53:852–64.
   PubMed Web of Science ®Google Scholar
• Bockelman C, Engelmann BE, Kaprio T, Hansen TF, Glimelius B. Risk of recurrence in patients with colon cancer stage II and III: A systematic review and meta-analysis of recent literature. Acta Oncol 2015;54:5–16.
   PubMed Web of Science ®Google Scholar
• Poulsen LO, Qvortrup C, Pfeiffer P, Yilmaz M, Falkmer U, Sorbye H. Review on adjuvant chemotherapy for rectal cancer – why do treatment guidelines differ so much? Acta Oncol Epub 2015;54:437–46.
   PubMed Web of Science ®Google Scholar
• Gill S, Loprinzi CL, Sargent DJ, Thome SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 2004;22:1797–806.
   PubMed Web of Science ®Google Scholar
• Jonker DJ, Spithoff K, Maroun J. Adjuvant systemic chemotherapy for Stage II and III colon cancer after complete resection: An updated practice guideline. Clin Oncol (R Coll Radiol) 2011;23:314–22.
   PubMed Web of Science ®Google Scholar
• Kohne CH. Current stages of adjuvant treatment of colon cancer. Ann Oncol 2012;23(Suppl 10):x71–6.
   PubMed Web of Science ®Google Scholar
• Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008;3:CD005390.
   Google Scholar
• Adjuvant!Online.Adjuvant!Inc. [cited 2014 Dec 22]. Available from: http://www.adjuvantonline.com.
   Google Scholar
• Dahl O, Pfeffer F. Twenty-five years with adjuvant chemotherapy for colon cancer – a continuous evolving concept. Acta Oncol 2015;54:1–4.
   PubMed Web of Science ®Google Scholar
• Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012;3:CD004078.
   Google Scholar
• Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic- Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: Long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014;15:184–90.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, et al. Chronicle: Results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 2014;25:1356–62.
   PubMed Web of Science ®Google Scholar
• Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER, Lupattelli M, et al. No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT). Radiother Oncol 2014;113:223–9.
   PubMed Web of Science ®Google Scholar
• Breugom AJ, van Gijn W, Muller EW, Berglund A, van den Broek CB, Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: A Dutch Colorectal Cancer Group (DCCG) randomised phase III trial. Ann Oncol Epub 2014 Dec 5.
   Google Scholar
• Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: A systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16:200–7.
   PubMed Web of Science ®Google Scholar
• Maas M, Nelemans PJ, Valentini V, Crane CH, Capirci C, Rodel C, et al. Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. Int J Cancer Epub 2014 Nov 22.
   Google Scholar
• Beets GL, Glimelius BL. Adjuvant chemotherapy for rectal cancer still controversial. Lancet Oncol 2014;15:130–1.
   PubMed Web of Science ®Google Scholar
• Cervantes A, Glynne-Jones R. Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: One size does not fit all. Ann Oncol Epub 2015 Jan 20.
   Google Scholar
• Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27:872–7.
   PubMed Web of Science ®Google Scholar
• van den Broek CB, Bastiaannet E, Dekker JW, Portielje JE, de Craen AJ, Elferink MA, et al. Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients – a large population-based study from 1990 to 2008. Acta Oncol 2013;52:941–9.
   PubMed Web of Science ®Google Scholar
• Nedrebo BS, Soreide K, Eriksen MT, Kvaloy JT, Soreide JA, Korner H. Excess mortality after curative surgery for colorectal cancer changes over time and differs for patients with colon versus rectal cancer. Acta Oncol 2013;52:933–40.
   PubMed Web of Science ®Google Scholar
• Engelhardt EG, de Haes HC, van de Velde CJ, Smets EM, Pieterse AH, Stiggelbout AM. Oncologists’ weighing of the benefits and side effects of adjuvant systemic therapy: Has it changed over time? Acta Oncol Epub 2015 Jan 16:1–4.
   PubMedGoogle Scholar
• Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomised trial. Lancet 2009;373:811–20.
   PubMed Web of Science ®Google Scholar
• Glimelius B. Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future. Ups J Med Sci 2012;117:225–36.
   PubMed Web of Science ®Google Scholar
• van Gijn W, van Stiphout RG, van de Velde CJ, Valentini V, Lammering G, Gambacorta MA, et al. Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapy. Ann Oncol Epub 2015 Jan 21.
   Google Scholar
• Andre T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration: Prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: Trial design and current status. Curr Colorectal Cancer Rep 2013;9:261–9.
   PubMedGoogle Scholar